지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.9
- 수록면
- 124 - 138 (15page)
이용수
초록· 키워드
오류제보하기
Several molecular-targeted agents have been tested as first- or second-line therapies for hepatocellular carcinoma (HCC) but failed to improve clinical outcomes; sorafenib has been the only approved systemic agent for treating HCC for almost 10 years. Regorafenib resulted in a significant improvement in overall survival and thus was approved for HCC patients previously treated with sorafenib. Subsequently, cabozantinib and ramucirumab demonstrated superior overall survival compared with placebos in phase III clinical trials. Immune checkpoint inhibitors such as nivolumab with or without ipilimumab and pembrolizumab are also available in some countries for patients who are unresponsive to sorafenib. Some second-line agents are available for patients who are unresponsive to sorafenib; however, little is known about the considerations for selecting appropriate second?line systemic agents. Hence, this study aimed to review the current and future perspectives of second-line systemic agents.
목차
등록된 정보가 없습니다.
참고문헌 (28)
참고문헌 신청
Bruix J / 2017 / Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, doubleblind, placebo-controlled, phase 3 trial / Lancet 389:56~66
Finn RS / 2018 / Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC : additional analyses from the phase III RESORCE trial / J Hepatol 69:353~358
Abou-Alfa GK / 2018 / Cabozantinib in patients with advanced and progressing hepatocellular carcinoma / N Engl J Med 379:54~63
Kelley RK / 2020 / Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma : a subgroup analysis of the phase 3 CELESTIAL trial / ESMO Open 5:e000714
Zhu AX / 2015 / Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial / Lancet Oncol 16:859~870
Finn RS / 2018 / Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC : additional analyses from the phase III RESORCE trial / J Hepatol 69:353~358
Abou-Alfa GK / 2018 / Cabozantinib in patients with advanced and progressing hepatocellular carcinoma / N Engl J Med 379:54~63
Kelley RK / 2020 / Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma : a subgroup analysis of the phase 3 CELESTIAL trial / ESMO Open 5:e000714
Zhu AX / 2015 / Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial / Lancet Oncol 16:859~870
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
Clinical and Molecular Hepatology
2015 .01
-
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
Clinical and Molecular Hepatology
2020 .01
-
Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib
Yonsei Medical Journal
2017 .01
-
Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
Cancer Research and Treatment
2016 .01
-
Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure
Journal of Liver Cancer
2020 .01
-
A Case of Achieving Partial Remission with the Combination of Sorafenib and Nivolumab in a Patient with Hepatocellular Carcinoma Showing Disease Progression after Nivolumab Therapy
Journal of Liver Cancer
2019 .01
-
A case report of advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy and sorafenib combination therapy followed by metastasectomy of lung and muscle metastases
Journal of Liver Cancer
2022 .03
-
Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report
Journal of Liver Cancer
2021 .09
-
Tumor lysis syndrome following sorafenib treatment in hepatocellular carcinoma
영남의대학술지
2015 .01
-
Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review
Clinical and Molecular Hepatology
2017 .01
-
HCC 재발환자에서 sorafenib 적용 증례
WITH CAP(COMPANION ANIMAL PRACTICE)
2021 .04
-
An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib
Annals of Hepato-Biliary-Pancreatic Surgery
2015 .02
-
폐전이를 보인 단일결절형 거대 간세포암종 환자에서 순차적인 경동맥화학색전술과 Sorafenib으로 완전관해를 보인 1예
Journal of Liver Cancer
2016 .01
-
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Clinical and Molecular Hepatology
2023 .04
-
Usefulness of sarcopenia in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment
대한외과학회 학술대회 초록집
2019 .10
-
The strategy for the treatment of hepatocellular carcinoma
대한동의병리학회 학술대회논문집
2015 .10
-
Effects of the mixed formulation of sorafenib and blue honeysuckle on the pharmacokinetics profiles of sorafenib
대한예방한의학회지
2019 .01
-
Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
Journal of Korean Medical Science
2018 .01
-
Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation
Journal of Liver Cancer
2020 .01
-
Recent Advances and Future Directions in Immunotherapeutics for Hepatocellular Carcinoma
Journal of Liver Cancer
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0